BE2017C009I2 - - Google Patents

Info

Publication number: BE2017C009I2
Authority: BE; Belgium

Application number

BE2017C009C

Other languages

Original Assignee

Millennium Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-14

Filing date

2017-04-11

Publication date

2017-09-22

2017-04-11 Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc

2017-09-22 Publication of BE2017C009I2 publication Critical patent/BE2017C009I2/nl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Mycology (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Reproductive Health (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Gynecology & Obstetrics (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Rheumatology (AREA)
Pregnancy & Childbirth (AREA)
Transplantation (AREA)
Obesity (AREA)

BE2017C009C 2000-04-14 2017-04-11 BE2017C009I2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US55008200A	2000-04-14	2000-04-14
US09/748,960 US20010046496A1 (en)	2000-04-14	2000-12-27	Method of administering an antibody

Publications (1)

Publication Number	Publication Date
BE2017C009I2 true BE2017C009I2 (en)	2017-09-22

Family

ID=27069332

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BE2017C009C BE2017C009I2 (en)	2000-04-14	2017-04-11

Country Status (16)

Country	Link
US (5)	US20010046496A1 (en)
EP (3)	EP3167902B1 (en)
JP (3)	JP2003531129A (en)
AU (1)	AU2001251629A1 (en)
BE (1)	BE2017C009I2 (en)
CA (1)	CA2406220C (en)
CY (3)	CY1113489T1 (en)
DK (2)	DK1278543T3 (en)
ES (2)	ES2398096T3 (en)
FR (1)	FR14C0080I2 (en)
HK (1)	HK1054320A1 (en)
LU (1)	LUC00014I2 (en)
MX (1)	MXPA02010059A (en)
NL (1)	NL300702I2 (en)
PT (1)	PT2298348T (en)
WO (1)	WO2001078779A2 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7658924B2 (en) *	2001-10-11	2010-02-09	Amgen Inc.	Angiopoietin-2 specific binding agents
US7521053B2 (en)	2001-10-11	2009-04-21	Amgen Inc.	Angiopoietin-2 specific binding agents
CA2477178A1 (en)	2002-02-25	2003-09-04	Elan Pharmaceuticals, Inc.	Administration of agents for the treatment of inflammation
SG187991A1 (en)	2002-05-02	2013-03-28	Wyeth Corp	Calicheamicin derivative-carrier conjugates
GB0210121D0 (en) *	2002-05-02	2002-06-12	Celltech R&D Ltd	Biological products
DOP2005000002A (en) *	2004-01-09	2005-08-15	Pfizer	"ANTIBODIES AGAINST MADCAM"
MX341370B (en)	2004-09-03	2016-08-17	Genentech Inc	Humanized anti-beta7 antagonists and uses therefor.
PE20070374A1 (en) *	2005-07-08	2007-05-12	Pfizer Ltd	ANTI-MADCAM ANTIBODIES
WO2007007152A2 (en) *	2005-07-11	2007-01-18	Pfizer Limited	Anti-madcam antibodies to treat metastatic cancers and chloroma
AU2006267976B2 (en) *	2005-07-11	2009-12-24	Pfizer Limited	New combination of anti-madcam antibody and antifibrotic caspase inhibitor to treat liver fibrosis
CA2675291C (en)	2007-01-11	2017-05-23	Novo Nordisk A/S	Killer ig-like receptor (kir) antibodies, formulations, and uses thereof
EP2125892A2 (en) *	2007-03-20	2009-12-02	Millennium Pharmaceuticals, Inc.	Nucleic acids encoding humanized immunoglobulin that binds a4b7 integrin
WO2009026117A2 (en) *	2007-08-16	2009-02-26	Glaxo Group Limited	Novel compounds
JO2913B1 (en)	2008-02-20	2015-09-15	امجين إنك,	Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
SI2279004T1 (en) *	2008-05-16	2015-05-29	F. Hoffmann-La Roche Ag	Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7integrin antagonists
TWI466681B (en)	2009-03-20	2015-01-01	Amgen Inc	Alpha4beta7 heterodimer specific antagonist antibody
CA2807552A1 (en)	2010-08-06	2012-02-09	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
HUE058896T2 (en)	2010-10-01	2022-09-28	Modernatx Inc	Ribonucleic acids containing n1-methyl-pseudouracils and uses thereof
EP2691101A2 (en)	2011-03-31	2014-02-05	Moderna Therapeutics, Inc.	Delivery and formulation of engineered nucleic acids
EP4438625A2 (en) *	2011-05-02	2024-10-02	Millennium Pharmaceuticals, Inc.	Formulation for anti-alpha4beta7 antibody
UA116189C2 (en) *	2011-05-02	2018-02-26	Мілленніум Фармасьютікалз, Інк.	FORMULATION FOR ANTI-α4β7 ANTIBODY
US9464124B2 (en)	2011-09-12	2016-10-11	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
HUE057725T2 (en)	2011-10-03	2022-06-28	Modernatx Inc	Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
MX366936B (en) *	2011-11-23	2019-07-31	Amgen Inc	Administration of alpha4beta7 hetero-dimer-specific antibody.
CA3018046A1 (en)	2011-12-16	2013-06-20	Moderna Therapeutics, Inc.	Modified nucleoside, nucleotide, and nucleic acid compositions
EA034583B1 (en) *	2012-01-12	2020-02-21	Милленниум Фармасьютикалз, Инк.	USES OF ANTI-α4β7 ANTIBODY
EP2834358A4 (en)	2012-04-02	2016-03-09	Moderna Therapeutics Inc	Modified polynucleotides for the production of nuclear proteins
US9283287B2 (en)	2012-04-02	2016-03-15	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en)	2012-04-02	2017-02-21	Modernatx, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9303079B2 (en)	2012-04-02	2016-04-05	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
DK2922554T3 (en)	2012-11-26	2022-05-23	Modernatx Inc	Terminalt modificeret rna
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
US10023626B2 (en)	2013-09-30	2018-07-17	Modernatx, Inc.	Polynucleotides encoding immune modulating polypeptides
CN105980401A (en)	2013-10-03	2016-09-28	现代治疗公司	Polynucleotides encoding low density lipoprotein receptor
US20170327584A1 (en)	2014-11-26	2017-11-16	Millennium Pharmaceuticals, Inc.	Vedolizumab for the Treatment of Fistulizing Crohn's Disease
WO2016105572A1 (en)	2014-12-24	2016-06-30	Millennium Pharmaceuticals, Inc.	PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-α4β7 INTEGRIN ANTIBODY
US20190077868A1 (en)	2016-03-14	2019-03-14	Millennium Pharmaceuticals, Inc.	Methods of treating or preventing graft versus host disease
CN109071660A (en)	2016-03-14	2018-12-21	千禧制药公司	The method for preventing graft versus host disease
WO2017165742A1 (en)	2016-03-24	2017-09-28	Millennium Pharmaceuticals, Inc.	Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
US11760803B2 (en)	2016-03-24	2023-09-19	Takeda Pharmaceutical Company Limited	Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
EP3452070A1 (en)	2016-05-04	2019-03-13	Millennium Pharmaceuticals, Inc.	Triple combination therapy for treating inflammatory bowel disease
JP7202893B2 (en)	2016-06-12	2023-01-12	武田薬品工業株式会社	How to treat inflammatory bowel disease
BR112020000698A2 (en)	2017-07-14	2020-07-14	Pfizer Inc.	antibodies against madcam
US20230139938A1 (en) *	2021-09-21	2023-05-04	University Of South Carolina	Anti-CCL8 Antibodies and Treatment of Lung Injury by CCL8 Inhibition

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4172124A (en)	1978-04-28	1979-10-23	The Wistar Institute	Method of producing tumor antibodies
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
WO1988007089A1 (en)	1987-03-18	1988-09-22	Medical Research Council	Altered antibodies
EP0318554B2 (en)	1987-05-21	2005-01-12	Micromet AG	Targeted multifunctional proteins
US5538724A (en) *	1987-08-11	1996-07-23	The Board Of Trustees For The Leland Stanford Junior Univ.	Method of control leukocyte extravasation
US5403919A (en) *	1987-08-11	1995-04-04	Board Of Trustees Of The Leland Stanford Junior University Stanford University	Method to control leukocyte extravasation
JP3095168B2 (en)	1988-02-05	2000-10-03	エル．モリソン，シェリー	Antibodies with domain-denaturing constants
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5859205A (en) *	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
DE69120146T2 (en)	1990-01-12	1996-12-12	Cell Genesys Inc	GENERATION OF XENOGENIC ANTIBODIES
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
EP0519596B1 (en)	1991-05-17	2005-02-23	Merck & Co. Inc.	A method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en)	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
EP0590058B1 (en) *	1991-06-14	2003-11-26	Genentech, Inc.	HUMANIZED Heregulin ANTIBODy
DK0605522T3 (en)	1991-09-23	2000-01-17	Medical Res Council	Process for producing humanized antibodies
US5871734A (en) *	1992-01-13	1999-02-16	Biogen, Inc.	Treatment for asthma with VLA-4 blocking agents
US5932214A (en) *	1994-08-11	1999-08-03	Biogen, Inc.	Treatment for inflammatory bowel disease with VLA-4 blockers
AU687790B2 (en) *	1993-02-09	1998-03-05	Biogen Idec Ma Inc.	Treatment for insulin dependent diabetes
CA2115811A1 (en)	1993-02-17	1994-08-18	Claus Krebber	A method for in vivo selection of ligand-binding proteins
AU691811B2 (en)	1993-06-16	1998-05-28	Celltech Therapeutics Limited	Antibodies
US5840299A (en)	1994-01-25	1998-11-24	Athena Neurosciences, Inc.	Humanized antibodies against leukocyte adhesion molecule VLA-4
GB2292079B (en) *	1994-08-12	1998-07-15	Flexpharm Ltd	Coated prednisolone preparation for the treatment of inflamatory bowel disease
US6551593B1 (en) *	1995-02-10	2003-04-22	Millennium Pharmaceuticals, Inc.	Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US6015662A (en) *	1996-01-23	2000-01-18	Abbott Laboratories	Reagents for use as calibrators and controls
US7147851B1 (en) *	1996-08-15	2006-12-12	Millennium Pharmaceuticals, Inc.	Humanized immunoglobulin reactive with α4β7 integrin
EP2305027B1 (en)	1996-12-03	2014-07-02	Amgen Fremont Inc.	Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
EP1113810B1 (en) *	1998-09-14	2008-12-31	Board of Regents, The University of Texas System	Methods of treating multiple myeloma and myeloma-induced bone resorption using antagonists of integrin / receptor binding

2000
- 2000-12-27 US US09/748,960 patent/US20010046496A1/en not_active Abandoned
2001
- 2001-04-13 PT PT100109974T patent/PT2298348T/en unknown
- 2001-04-13 JP JP2001576078A patent/JP2003531129A/en not_active Withdrawn
- 2001-04-13 EP EP16191558.2A patent/EP3167902B1/en not_active Revoked
- 2001-04-13 MX MXPA02010059A patent/MXPA02010059A/en active IP Right Grant
- 2001-04-13 ES ES01925028T patent/ES2398096T3/en not_active Expired - Lifetime
- 2001-04-13 DK DK01925028.1T patent/DK1278543T3/en active
- 2001-04-13 EP EP10010997.4A patent/EP2298348B9/en not_active Expired - Lifetime
- 2001-04-13 EP EP01925028A patent/EP1278543B1/en not_active Expired - Lifetime
- 2001-04-13 AU AU2001251629A patent/AU2001251629A1/en not_active Abandoned
- 2001-04-13 ES ES10010997.4T patent/ES2609689T3/en not_active Expired - Lifetime
- 2001-04-13 DK DK10010997.4T patent/DK2298348T3/en active
- 2001-04-13 WO PCT/US2001/012234 patent/WO2001078779A2/en active Application Filing
- 2001-04-13 CA CA2406220A patent/CA2406220C/en not_active Expired - Lifetime
2003
- 2003-07-29 HK HK03105456.3A patent/HK1054320A1/en unknown
- 2003-12-15 US US10/735,863 patent/US20050095238A1/en not_active Abandoned
2011
- 2011-08-05 US US13/204,139 patent/US20120034243A1/en not_active Abandoned
2012
- 2012-05-02 JP JP2012105379A patent/JP5764524B2/en not_active Expired - Lifetime
- 2012-12-18 CY CY20121101236T patent/CY1113489T1/en unknown
2014
- 2014-02-03 US US14/171,161 patent/US20140186345A1/en not_active Abandoned
- 2014-11-11 NL NL300702C patent/NL300702I2/nl unknown
- 2014-11-13 FR FR14C0080C patent/FR14C0080I2/en active Active
- 2014-11-17 CY CY2014046C patent/CY2014046I1/en unknown
2015
- 2015-01-19 JP JP2015007655A patent/JP6021959B2/en not_active Expired - Lifetime
2017
- 2017-01-05 CY CY20171100013T patent/CY1118429T1/en unknown
- 2017-04-11 LU LU00014C patent/LUC00014I2/fr unknown
- 2017-04-11 BE BE2017C009C patent/BE2017C009I2/nl unknown
2018
- 2018-11-02 US US16/179,157 patent/US20200002423A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP2003531129A (en)	2003-10-21
MXPA02010059A (en)	2004-08-19
WO2001078779A3 (en)	2002-07-04
US20010046496A1 (en)	2001-11-29
JP2015083603A (en)	2015-04-30
JP6021959B2 (en)	2016-11-09
DK2298348T3 (en)	2017-01-30
EP3167902A1 (en)	2017-05-17
NL300702I1 (en)	2016-01-28
US20140186345A1 (en)	2014-07-03
ES2609689T3 (en)	2017-04-21
EP2298348B9 (en)	2017-02-15
PT2298348T (en)	2017-01-04
CY1113489T1 (en)	2016-04-13
US20200002423A1 (en)	2020-01-02
JP5764524B2 (en)	2015-08-19
NL300702I2 (en)	2016-01-28
EP2298348A1 (en)	2011-03-23
EP3167902B1 (en)	2020-07-29
FR14C0080I2 (en)	2015-10-30
CY1118429T1 (en)	2017-06-28
EP2298348B1 (en)	2016-10-12
DK1278543T3 (en)	2013-01-14
EP1278543A2 (en)	2003-01-29
AU2001251629A1 (en)	2001-10-30
US20120034243A1 (en)	2012-02-09
EP1278543B1 (en)	2012-09-19
JP2012184241A (en)	2012-09-27
FR14C0080I1 (en)	2014-12-19
CA2406220A1 (en)	2001-10-25
CA2406220C (en)	2019-02-12
CY2014046I2 (en)	2016-04-13
ES2398096T3 (en)	2013-03-13
CY2014046I1 (en)	2016-04-13
HK1054320A1 (en)	2003-11-28
WO2001078779A2 (en)	2001-10-25
US20050095238A1 (en)	2005-05-05
LUC00014I2 (en)	2017-06-19
LUC00014I1 (en)	2017-04-18

Publication	Publication Date	Title
BE2017C009I2 (en)	2017-09-22
BE2016C018I2 (en)	2020-08-20
JP2002537716A5 (en)	2005-06-23
BRPI0110940B8 (en)	2021-05-25
JP2001063310A5 (en)	2011-01-06
JP2003529114A5 (en)	2007-02-22
JP2001346384A5 (en)	2005-10-27
JP2002025989A5 (en)	2007-04-26
JP2002541950A5 (en)	2007-06-07
JP2002135858A5 (en)	2007-02-15
JP2003530142A5 (en)	2007-12-06
JP2001195509A5 (en)	2007-05-24
JP2001296414A5 (en)	2007-05-31
JP2001251115A5 (en)	2008-09-25
JP2002158917A5 (en)	2008-01-10
JP2002006216A5 (en)	2007-06-28
JP2002011238A5 (en)	2007-06-28
BR0112866A2 (en)	2009-12-08
JP2001297727A5 (en)	2007-05-31
JP2002089068A5 (en)	2008-08-14
BRPI0000763B8 (en)	2021-06-22
CN3139850S (en)	2000-02-23
CN3135488S (en)	2000-01-19
CN3135513S (en)	2000-01-19
CN3135585S (en)	2000-01-19